
Bavarian Nordic has scheduled its phase III trial of its booster candidate against Covid-19, dubbed ABNCoV2, in August, according to a press release.
In April, MedWatch reported that Bavarian Nordic’s study would compare a booster dose of ABNCov2 versus Pfizer/Biontech’s Comirnaty in previously vaccinated adult subjects, with the primary outcome measure being to demonstrate non-inferiority in terms of antibodies against the original strain of Covid-19.
Already a subscriber? Log in.
Read the whole article
Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
- Access all locked articles
- Receive our daily newsletters
- Access our app